Orexo’s OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC

Orexo AB, announces the presentation of its nasal epinephrine powder product OX640 at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting.